The Autonomous Reanimation and Evacuation Research Institute and SeaStar Medical (ICU) announced that a new United States Department of Defense grant has been awarded to AREVA. The grant is one of four selected out of 160 total submissions by the 2024 Military Burn Research Program and represents cutting-edge research for extracorporeal immunomodulation to reduce inflammation after severe burns, inhalation injury, and septicemia. The grant supports a three-year research study that is scheduled to begin in July 2025 with more than $2 million in DoD funding. The study will explore the application of SeaStar Medical’s Selective Cytopheretic Device therapy to reduce hyperinflammation in warfighters after severe burns, inhalation injury, and infection. The award represents a significant step towards the advancement of extracorporeal immunomodulation through the use of the SCD therapy, an innovative therapeutic device designed to neutralize destructive hyperinflammation, to improve survival in both combat casualties and civilian patients suffering from severe trauma and infection. Used alongside continuous renal replacement therapy, the SCD therapy is designed to support organ recovery and may reduce the need for dialysis in patients with severe acute inflammatory conditions.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICU:
- SeaStar announces CMS coverage for Medicare, Medicaid in NEUTRALIZE-CRS trial
- SeaStar Medical files to sell 4.74M shares of common stock for holders
- SeaStar Medical Holding: Strong Buy Rating Backed by Impressive Revenue Growth and Strategic Advancements
- Seastar Medical’s Earnings Call Highlights Growth and Challenges
- SeaStar Medical Reports Strong Q1 2025 Growth